HPB-092

News alerts, weekly reports and conference planners

Company:

Polymed Biopharma

Drug class:

FLT3 inhibitor, IRAK-4 inhibitor

U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D

Associations
(2)